Buy & Sell Caesars Entertainment Inc (CZR) – Caesars Entertainment Inc Price Today
Aura AI Summary
Key Stats
- $5.80BMarket Cap
- Consumer CyclicalSector
- -12.59%3M Drawdown
- $29.86BEnterprise Value
- -Dividend Yield
- 24 daysTypical Hold Time
Caesars Entertainment Inc (CZR) is currently valued at a market capitalization of $5.80B, with an enterprise value of $29.86B. Over the past 52 weeks, Caesars Entertainment Inc has traded between a low of $18.14 and a high of $31.51, highlighting its annual price range. Over the past three months, Caesars Entertainment Inc has recorded a drawdown of -12.59%, reflecting recent price volatility. On average, investors hold Caesars Entertainment Inc for approximately 24 days, indicating typical investor behavior on the platform.
About Caesars Entertainment Inc
Caesars Entertainment includes around 50 domestic gaming properties across Las Vegas (50% of 2021 EBITDAR before corporate and digital expenses) and regional (63%) markets. Additionally, the company hosts managed properties and digital assets, the later of which produced material EBITDA losses in 2021. Caesars' U.S. presence roughly doubled with the 2020 acquisition by Eldorado, which built its first casino in Reno, Nevada, in 1973 and expanded its presence through prior acquisitions to over 20 properties before merging with legacy Caesars. Caesars' brands include Caesars, Harrah's, Tropicana, Bally's, Isle, and Flamingo. Also, the company owns the U.S. portion of William Hill (it plans to sell the international operation in 2022), a digital sports betting platform.
Most Recent News
Microneedle drug delivery market to double to $14.37B by 2035, driven by pain-free therapies and vaccine tech.
The global microneedle drug delivery systems market is projected to grow from $7.04 billion in 2025 to $14.37 billion by 2035, at a CAGR of 7.4%. Growth is fueled by rising demand for minimally invasive, pain-free, and self-administered drug delivery...
Hansa Biopharma to present positive 12-month Phase 3 kidney transplant trial results at American Transplant Congress.
Hansa Biopharma announced that its Phase 3 ConfIdeS trial results for kidney transplantation in highly sensitized patients will be presented at the American Transplant Congress on June 22, 2026. The presentation will detail 12-month outcomes, includi...
TruBridge faces class action over financial errors and late report filing, shares drop 10.5%.
TruBridge, Inc. disclosed errors in its previously issued financial statements for 2023 and 2024, leading to a late filing of its 2025 annual report. The errors involve revenue recognition, contract costs, stock-based compensation, and capitalized so...
